Study S002029

A Randomized Clinical Trial to Study Glucose Dependent Insulin Secretion Methodologies in Healthy Lean Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00782418
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 27
Start: 2008-09
Primary completion: 2009-02
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: The Methodology Assessment of Glucose Dependent Insulin Secretion
Interventions: DRUG:Comparator: exenatide; DRUG:Comparator: Placebo
Results posted: TRUE
Secondary identifiers: OTHER:2008_568

Registered primary outcomes

Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose [Steady-state of HGC: 90 - 120 minutes post dose; highest glucose infusion rate of GGI: 120 - 160 minutes post dose]
Change From Baseline in C-peptide Concentration [Pre and Post glucose infusion]
Change From Baseline in Insulin Concentration [Pre and Post glucose infusion]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0028793	Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series. Shankar SS, American journal of physiology. Endocrinology and metabolism	2016	Other trial	PMID 27072496 DOI	cites ClinicalTrials.gov:NCT00782418; registry reference RESULT:27072496